Appeals court sides with FDA in lawsuit over fat-derived stem cell procedure
The FDA’s crack down on stem cell clinics hawking unapproved products for conditions with limited options is off and running, with a new court win for the agency at the 11th Circuit of Appeals on Wednesday.
The court found that Florida-based US Stem Cell’s biological material implanted into the patient “is not the same as that removed,” and the procedure “intends the stem cells to perform functions after the procedure beyond the basic functions the stem cells performed prior to the procedure.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.